10 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 32096250 | Antifibrogenic effects of C-C chemokine receptor type 2 antagonist in a bleomycin-induced scleroderma model. | 2021 Jan | 2 |
2 | 32673071 | Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. | 2021 Jan 1 | 1 |
3 | 32253243 | IRAK-M Regulates Monocyte Trafficking to the Lungs in Response to Bleomycin Challenge. | 2020 May 15 | 1 |
4 | 30470612 | Evaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3. | 2018 Dec | 1 |
5 | 27777976 | Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome. | 2016 Oct 20 | 1 |
6 | 24507087 | Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. | 2014 Feb 8 | 1 |
7 | 15538737 | C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. | 2004 Dec | 4 |
8 | 12925209 | Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. | 2003 Sep | 3 |
9 | 14609568 | CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. | 2003 Dec 21 | 1 |
10 | 11591761 | Protection from pulmonary fibrosis in the absence of CCR2 signaling. | 2001 Oct 15 | 1 |